Top ▲

AKT serine/threonine kinase 2

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 1480

Nomenclature: AKT serine/threonine kinase 2

Abbreviated Name: Akt2

Family: Akt (Protein kinase B, PKB) family

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 481 19q13.2 AKT2 AKT serine/threonine kinase 2
Mouse - 481 7 15.94 cM Akt2 thymoma viral proto-oncogene 2
Rat - 481 1q21 Akt2 AKT serine/threonine kinase 2
Previous and Unofficial Names Click here for help
AKT2 kinase | PKB beta | RAC protein kinase beta RAC-PK beta | RAC-PK-beta | protein kinase B beta | PKB2 | RAC-beta serine/threonine-protein kinase | v-akt murine thymoma viral oncogene homolog 2
Database Links Click here for help
Alphafold P31751 (Hs), Q60823 (Mm), P47197 (Rn)
BRENDA 2.7.11.11
CATH/Gene3D 2.30.29.30
ChEMBL Target CHEMBL2431 (Hs), CHEMBL5382 (Mm)
Ensembl Gene ENSG00000105221 (Hs), ENSMUSG00000004056 (Mm), ENSRNOG00000018677 (Rn)
Entrez Gene 208 (Hs), 11652 (Mm), 25233 (Rn)
Human Protein Atlas ENSG00000105221 (Hs)
KEGG Enzyme 2.7.11.11
KEGG Gene hsa:208 (Hs), mmu:11652 (Mm), rno:25233 (Rn)
OMIM 164731 (Hs)
Orphanet ORPHA201112 (Hs)
Pharos P31751 (Hs)
RefSeq Nucleotide NM_001243027 (Hs), NM_007434 (Mm), NM_017093 (Rn)
RefSeq Protein NP_001617 (Hs), NP_031460 (Mm), NP_001103678 (Mm), NP_058789 (Rn)
SynPHARM 81449 (in complex with GSK690693)
UniProtKB P31751 (Hs), Q60823 (Mm), P47197 (Rn)
Wikipedia AKT2 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
PDB Id:  1GZO
Resolution:  2.75Å
Species:  Human
References:  22
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of human Akt2 in complex with GSK690693
PDB Id:  3D0E
Ligand:  GSK690693
Resolution:  2.0Å
Species:  Human
References:  10
Enzyme Reaction Click here for help
EC Number: 2.7.11.11

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
A-443654 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition ~9.8 pKi 14
⤷ pKi ~9.8 (Ki ~1.6x10-10 M) [14]
uprosertib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.9 pKi 8
⤷ pKi 8.9 (Ki 1.4x10-9 M) [8]
afuresertib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.7 pKi 8
⤷ pKi 8.7 (Ki 2x10-9 M) [8]
PHT-427 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 5.6 pKi 16
⤷ pKi 5.6 (Ki 2.67x10-6 M) [16]
Description: Assay using purified recombinant pleckstrin homology domain of human Akt2
compound E22 [PMID: 31298542] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.9 pIC50 7
⤷ pIC50 8.9 (IC50 1.2x10-9 M) [7]
miransertib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.9 pIC50 23
⤷ pIC50 8.9 (IC50 1.4x10-9 M) [23]
pifusertib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.8 pIC50 17
⤷ pIC50 8.8 (IC50 1.6x10-9 M) [17]
NTQ1062 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.2 pIC50 15
⤷ pIC50 8.2 (IC50 6.3x10-9 M) [15]
capivasertib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.1 pIC50 1
⤷ pIC50 8.1 (IC50 8x10-9 M) [1]
compound 1 [PMID: 20005102] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.9 pIC50 12
⤷ pIC50 7.9 (IC50 1.2x10-8 M) [12]
GSK690693 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.9 pIC50 10
⤷ pIC50 7.9 (IC50 1.3x10-8 M) [10]
ipatasertib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.7 pIC50 3
⤷ pIC50 7.7 (IC50 1.8x10-8 M) [3]
MS15 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.1 pIC50 23
⤷ pIC50 7.1 (IC50 9x10-8 M) [23]
Hu7691 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.0 pIC50 5
⤷ pIC50 7.0 (IC50 9.75x10-8 M) [5]
oridonin Small molecule or natural product Click here for species-specific activity table Hs Inhibition 5.1 pIC50 18
⤷ pIC50 5.1 (IC50 8.9x10-6 M) [18]
Inhibitor Comments
Note that A-443654 has similar potency across all three Akt isoforms [14].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
miransertib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.4 pIC50 11
⤷ pIC50 8.4 (IC50 4.5x10-9 M) [11]
MK-2206 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Negative 7.9 pIC50 20-21
⤷ pIC50 7.9 (IC50 1.2x10-8 M) [20-21]
BAY1125976 Small molecule or natural product Click here for species-specific activity table Hs Negative 7.7 pIC50 4
⤷ pIC50 7.7 (IC50 1.8x10-8 M) [4]
Description: Biochemical inhibition in a TR-FRET assay using full-length human AKT2 and biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG as substrate.
Akt inhibitor VIII Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Negative 6.7 pIC50 13
⤷ pIC50 6.7 (IC50 2.1x10-7 M) [13]
DiscoveRx KINOMEscan® screen Click here for help
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 6,19
Key to terms and symbols Click column headers to sort
Target used in screen: AKT2
Ligand Sp. Type Action Value Parameter
GSK690693 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.7 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
midostaurin Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 6.1 pKd
lestaurtinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 5.7 pKd
sunitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 5.6 pKd
A-674563 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 5.5 pKd
SB203580 Small molecule or natural product Immunopharmacology Ligand Hs Inhibitor Inhibition <5.5 pKd
erlotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition <5.5 pKd
crizotinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition <5.5 pKd
linifanib Small molecule or natural product Hs Inhibitor Inhibition <5.5 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen Click here for help
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx

Reference: 2,9
Key to terms and symbols Click column headers to sort
Target used in screen: PKBβ/AKT2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 5.5 5.0 1.5
SB 218078 Small molecule or natural product Hs Inhibitor Inhibition 48.5 101.0 92.0
PDK1/Akt/Flt dual pathway inhibitor Small molecule or natural product Hs Inhibitor Inhibition 55.8 133.0 44.0
H-89 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 75.4 86.0 36.0
midostaurin Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 77.2 80.0 46.0
TGF-beta RI inhibitor III Small molecule or natural product Hs Inhibitor Inhibition 80.1 115.0 95.0
AG1478 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 84.1 128.0 93.0
K-252a Small molecule or natural product Hs Inhibitor Inhibition 84.2 67.0 22.0
AG 1296 Small molecule or natural product Hs Inhibitor Inhibition 86.7 111.0 83.0
Cdk4 inhibitor Small molecule or natural product Hs Inhibitor Inhibition 86.9 102.0 77.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Diabetes mellitus, noninsulin-dependent; NIDDM
Synonyms: Diabetes mellitus, Type II; T2D [OMIM: 125853]
Maturity onset diabetes
Type 2 diabetes mellitus [Disease Ontology: DOID:9352]
Disease Ontology: DOID:9352
OMIM: 125853
Disease:  Familial partial lipodystrophy due to AKT2 mutations
Synonyms: Familial partial lipodystrophy [Disease Ontology: DOID:0050440]
Disease Ontology: DOID:0050440
Orphanet: ORPHA79085
Drugs:  Metreleptin
Disease:  Hypoinsulinemic hypoglycemia with hemihypertrophy
OMIM: 240900
Orphanet: ORPHA293964

References

Show »

1. Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R et al.. (2013) Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases. J Med Chem, 56 (5): 2059-73. [PMID:23394218]

2. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]

3. Blake JF, Xu R, Bencsik JR, Xiao D, Kallan NC, Schlachter S, Mitchell IS, Spencer KL, Banka AL, Wallace EM et al.. (2012) Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem, 55 (18): 8110-27. [PMID:22934575]

4. Bärfacker L, Scott W, Hägebarth A, Ince S, Rehwinkel H, Politz O, Neuhaus R, Briem H, Bömer U. (2012) Imidazopyridazines as Akt kinase inhibitors. Patent number: WO2012136776A1. Assignee: Bayer Pharma AG. Priority date: 07/04/2011. Publication date: 11/10/2012.

5. Che J, Dai X, Gao J, Sheng H, Zhan W, Lu Y, Li D, Gao Z, Jin Z, Chen B et al.. (2021) Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. J Med Chem, 64 (16): 12163-12180. [PMID:34375113]

6. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]

7. Dong X, Zhan W, Zhao M, Che J, Dai X, Wu Y, Xu L, Zhou Y, Zhao Y, Tian T et al.. (2019) Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem, 62 (15): 7264-7288. [PMID:31298542]

8. Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA et al.. (2014) Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE, 9 (6): e100880. [PMID:24978597]

9. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J, 451 (2): 313-28. [PMID:23398362]

10. Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW et al.. (2008) Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem, 51 (18): 5663-79. [PMID:18800763]

11. Lapierre JM, Eathiraj S, Vensel D, Liu Y, Bull CO, Cornell-Kennon S, Iimura S, Kelleher EW, Kizer DE, Koerner S et al.. (2016) Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem, 59 (13): 6455-69. [PMID:27305487]

12. Lin H, Yamashita DS, Zeng J, Xie R, Verma S, Luengo JI, Rhodes N, Zhang S, Robell KA, Choudhry AE et al.. (2010) 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett, 20 (2): 679-83. [PMID:20005102]

13. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE et al.. (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett, 15 (3): 761-4. [PMID:15664853]

14. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA et al.. (2005) Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther, 4 (6): 977-86. [PMID:15956255]

15. Ma C, Wu J, Wang L, Ji X, Wu Y, Miao L, Chen D, Zhang L, Wu Y, Feng H et al.. (2022) Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. J Med Chem, 65 (12): 8144-8168. [PMID:35679512]

16. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R et al.. (2010) Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther, 9 (3): 706-17. [PMID:20197390]

17. Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J et al.. (2014) Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res, 74 (16): 4458-69. [PMID:24934808]

18. Song M, Liu X, Liu K, Zhao R, Huang H, Shi Y, Zhang M, Zhou S, Xie H, Chen H et al.. (2018) Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo. Mol Cancer Ther, 17 (7): 1540-1553. [PMID:29695636]

19. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]

20. Yan L. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. Accessed on 18/11/2014. Modified on 18/11/2014. AACR Meeting Abstracts Online; http://aacrmeetingabstracts.org, http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2009/2_Annual_Meeting/DDT01-1?maxtoshow=&hits=10&RESULTFORMAT=1&title=MK-2206&andorexacttitle=and&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2008&tdate=12/31/2010&resourcetype=HWCIT

21. Yan L. (2009) MK-2206: a potent oral allosteric AKT inhibitor.[Abstract]. AACR Annual Meeting 2009,: Abstract Number: DDT01-1.

22. Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA, Barford D. (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell, 9 (6): 1227-40. [PMID:12086620]

23. Yu X, Xu J, Cahuzac KM, Xie L, Shen Y, Chen X, Liu J, Parsons RE, Jin J. (2022) Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. J Med Chem, 65 (20): 14237-14260. [PMID:36197750]

How to cite this page

Akt (Protein kinase B, PKB) family: AKT serine/threonine kinase 2. Last modified on 11/01/2024. Accessed on 24/01/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1480.